/* */ PELVIPHARM - Human prostatic tissue (control / BPH patients)
Receive our news

 

Human prostatic tissue (control / BPH patients)

Human prostatic tissues advantages

  • In vitro investigation of human prostate function in normal or in pathophysiological conditions.
  • Useful to investigate the effect of drugs developed to improve the dynamic component of prostatic lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH).
  • Evaluation of the ability of drugs at modulating prostatic smooth muscle tone can be performed
    • on adrenergic contractile response elicited by a-adrenergic pharmacological stimulation (phenylephrine/norepinephrine) or by electrical field stimulation (EFS) which stimulates efferent nerve terminals present in the tissue
    • on KCl response
    • on others relevant physiological precontracted states (endothelin-1, thromboxane agonist…)
  • Evaluation of mRNA by RT-PCR or protein expression, by immunohistochemistry (IHC) or western-blot (WB), in parallel of organ bath studies.

Source of human tissues sample

  • Human normal prostate samples are obtained from patients undergoing cystoprostatectomy for infiltrating bladder cancer.
  • Human BPH samples are obtained from patients diagnosed clinically for BPH and undergoing adenomectomy.
Figure 1: Original tracing showing the effect of cumulative addition of increasing concentrations of phenylephrine (M) on human prostatic tissue from BPH patient. (Pelvipharm, internal data)
Figure 1: Original tracing showing the effect of cumulative addition of increasing concentrations of phenylephrine (M) on human prostatic tissue from BPH patient. (Pelvipharm, internal data)


Figure 2: Effect of doxazosin on phenylephrine-induced contractions on human prostatic tissue from control patient. From Oger, S. et al. J Sex Med (2009) : 6(3) : 836-847.
Figure 2: Effect of doxazosin on phenylephrine-induced contractions on human prostatic tissue from control patient. From Oger, S. et al. J Sex Med (2009) : 6(3) : 836-847.


Endpoints

  • Evaluation of the capacity of a drug to inhibit prostatic smooth muscle contractions.
  • Determination of potency (EC50) and efficiency (Emax) of a drug.
  • Determination of the affinity (pA2) of a drug for a human prostatic receptor.
Related Pelvipharm bibliography
Oger, S. et al.
Eur Urol (2010) : 57(4):699-707

Oger, S. et al.
J Sex Med (2009) : 6(3):836-847

Giuliano, F. et al.
J Urol (2009) : 181(4):693 (AUA, 2009)
SITEMAP
TEL +331 704 293 39
FAX + 331 704 295 10
LEGAL